Enzyre

Executive Summary

Enzyre, a Dutch diagnostics company founded in 2016 and headquartered in Nijmegen, has developed the ENZYSYSTEM, a portable near-patient blood coagulation analysis platform. The system enables real-time testing and cloud-based data sharing, facilitating remote therapy management for patients with bleeding disorders such as hemophilia. By shifting coagulation monitoring from centralized labs to point-of-care settings, Enzyre addresses a critical need for timely, accessible diagnostics that can improve patient outcomes and reduce healthcare costs. The platform's connectivity features also support telemedicine and data-driven treatment adjustments, positioning it as a key enabler of personalized care in hematology. The global market for coagulation testing is expanding due to rising prevalence of bleeding disorders and an aging population. Enzyre's solution offers significant advantages in speed, portability, and remote monitoring, which could drive adoption among clinics, hospitals, and home-care providers. However, the company faces competition from established point-of-care systems and must navigate regulatory hurdles and reimbursement challenges. With its innovative technology and focus on patient-centric care, Enzyre is well-positioned to capture market share, though execution risk remains given its early stage. The company's success will depend on securing regulatory approvals, forming strategic partnerships, and demonstrating clinical utility.

Upcoming Catalysts (preview)

• Q2 2026CE Marking for ENZYSYSTEM in Europe75% success
• Q4 2026Strategic partnership with a global pharmaceutical company for distribution60% success
• Q3 2026Presentation of clinical validation data at a major hematology conference80% success